Preclinical development of EDIT-401, a durable in vivo CRISPR gene-editing therapy that upregulates LDLR protein to lower LDL-C ASGCT 29 th Annual Meeting, Boston, MA; May 11–15, 2026 Anshul Gupta, DVM, MS Vice President, Nonclinical Development…
Preclinical development of EDIT-401, a durable
in vivo CRISPR gene-editing therapy that
upregulates LDLR protein to lower LDL-C
ASGCT 29
th
Annual Meeting, Boston, MA; May 11–15, 2026
Anshul Gupta, DVM, MS
Vice President, Nonclinical Development
Editas Medicine, Inc., Cambridge, MA, United States.
Disclaimer: Anshul Gupta is an employee and equity holder of Editas Medicine, Inc.
UNDER EMBARGO UNTIL MAY 14, 2026
Introduction and Methods
UNDER EMBARGO UNTIL MAY 14, 2026
ASCVD is a serious disease with significant opportunity fora
transformative therapy to reduce LDL-C
ASCVD is driven by cholesterol-rich plaque accumulation in the arteries
• ASCVD is the primary cause of morbidity and mortality globally
1
, including in patients
with heterozygous familial hypercholesterolemia (HeFH), a genetic disease primarily
related to loss of function mutations in LDLR gene
2
• The link between lower LDL-C and reduced ASCVD risk is well established
1
• ~75% of patients with ASCVD do not meet LDL-C goals
3,4
• Standard of care requires multiple therapies and lifelong administration
1
Robust, lifelong reduction of LDL-C provides maximal benefit
5,6
4
- Arnett DK et al. Circulation 2019; 140 (11): e596–e646. 2. Gidding SS et al. J Am Heart Assoc 2025;14:e038458. 3. Gu J et al. Am J Prev Cardiol 2022; 10: 100336. 4. Klimchak AC et al. Am J Prev
Cardiol 2020; 1: 100010. 5. Cohen JC et al. N Engl J Med 2006; 354 (12): 1264–1272. 6. Gaba P et al. Circulation. 2023; 147 (16): 1192–1203.
ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.
UNDER EMBARGO UNTIL MAY 14, 2026
LDL-C:
•13–72 mg/dL plasma levels
(74% lower than population mean)
LDLR:
•1.5–2.5-fold higher surface LDLR*
Safety:
•No adverse events
Editas’ therapeutic strategy of LDLR upregulation for LDL-C reduction
was informed by human genetics
No adverse impacts on health
1
n = 101,857
Icelandic
non-carriers
Mean plasma LDL-C (mmol/L)
3'UTR deletion
carriers
Seven Icelandic family members identified as carriers of partial LDLR 3' UTR deletion
1
Plasma LDL-C levels
1
5
- Bjornsson E et al. Circ Genom Precis Med 2021; 14 (1): e003029.
*Noted value was for lymphocytes. Liver values are unknown. LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; UTR, untranslated region.
UNDER EMBARGO UNTIL MAY 14, 2026
EDIT-401 therapeutic strategy for LDLR upregulation
• CRISPR/Cas9 nuclease
and dual gRNAs disrupt
negative regulatory
elements of the LDLR
gene, increasing mRNA
stability, enabling ≥6-fold
increase in LDLR
protein in NHP
1
• This amplification
approach enables ≥90%
mean reduction in
serum LDL-C in NHPs
and mouse models with
high baseline LDL-C and
reduced LDLR function
1
EDIT-401 uses adifferentiated mechanism of action to reduce LDL-C
6
- Editas Medicine. Data on file.
Cas9, CRISPR-associated protein 9; CRISPR, clustered regularly interspaced short palindromic repeats; LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; LDL, low-density lipoprotein;
NHP, non-human primate.
UNDER EMBARGO UNTIL MAY 14, 2026
We conducted a series of studies to support the preclinical
development of EDIT-401
• NHP data (presented here)
Pharmacology
Biodistribution
Safety and tolerability
• Mouse data (Poster #3423):
"Pharmacokinetics and pharmacodynamics of EDIT-401(mu), in vivo gene-editing therapy for
lowering LDL-C in mice”
7
LDL-C, low-density lipoprotein cholesterol; NHP, non-human primates.
UNDER EMBARGO UNTIL MAY 14, 2026
Pharmacology
UNDER EMBARGO UNTIL MAY 14, 2026
CRISPR/Cas9 and dual gRNA-based strategy with LNP delivery
creates a potent approach to LDLR upregulation for LDL-C reduction
3' UTR, three prime untranslated region; Cas, CRISPR-associated protein; CRISPR, clustered regularly interspaced short palindromic repeats; HepG2, hepatoma G2 cells; LDL-C, low-density
lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; gRNA, guide RNA; mRNA, messenger RNA; WT, wild-type.
Clonal HepG2 Cell Lines
Functional edits increase LDLR protein
expression and LDL-C uptake
WT
Small indel
Excision
Inversion
0
2
4
6
8
10
LDLR protein (fold vs. WT)
LDLR protein
fold-upregulation
WT
Small indel
Excision
Inversion
0
1
2
3
4
5
LDL-C uptake
LDL-C mean fluorescence
(fold vs. WT)
9
• CRISPR/Cas9 nuclease and dual
gRNAs disrupt negative regulatory
elements in the 3' UTR, increasing
mRNA stability
• Functional editing events are the
result of targeted excisions or
inversions
• Non-functional editing events are
small indels resulting from the action
of one of the gRNAs
UNDER EMBARGO UNTIL MAY 14, 2026
EXPEDIT-401, CRISPR/Cas9 nuclease, and dual gRNAs for LDLR upregulation encapsulated in a GalNAc conjugated LNP administered to non-human primates
EDIT-401 achieved >90% mean LDL-C reduction by upregulating
LDLR; Dose Range Finding (DRF) Study data shown
10
Pre-dose LDL-C was averaged across two timepoints to account for variability in measurements. Day 1 defined as day of dosing. Mean values are shown +/- SD, with mean values of 89% at 1.5 mg/kg, and 94% for
all other dose groups at D29. Values below lower limit of quantitation assigned as LLoQ/2.
Cas9, CRISPR-associated protein 9; CRISPR, clustered regularly interspaced short palindromic repeats; D, day; GalNAc, N-acetylgalactosamine; gRNA, guide RNA; LDL-C, low-density lipoprotein cholesterol;
LDLR, low-density lipoprotein receptor; LLoQ, lower limit of quantification; LNP, lipid nanoparticle; NHP, non-human primate, LNPs licensed from Genevant Sciences Corporation.
Single dose of EDIT-401
• >90% mean LDL-C reduction
averaged across all dose groups
• Rapid LDL-C reduction observed
• Consistent data across 4
independent NHP studies
82%
94%
95%
Pre-dose
24h48h
D8
D15D22D29
-100
-90
-80
-70
-60
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
Time post dose
LDL-C
(% change from baseline)
Vehicle
(n=3)
1.5 mg/kg
(n=3)
3 mg/kg
(n=3)
6 mg/kg
(n=3)
UNDER EMBARGO UNTIL MAY 14, 2026
EDIT-401, CRISPR/Cas9 nuclease, and dual gRNAs for LDLR upregulation encapsulated in a GalNAc conjugated LNP administered to non-human primates
• Rapid LDL-C reduction
• Robust LDL-C reduction across
a dose range
• Durability of LDL-C reduction at
all doses through ~6 months
EDIT-401 displayed rapid, robust and durable LDL-C reduction
11
Pre-dose LDL-C was averaged across two timepoints to account for variability in measurements. Day 1 defined as day of dosing. Mean values are shown +/- SD, n=4/group.
Values below lower limit of quantitation assigned as LLoQ/2. ALT, alanine transaminase; AST, aspartate transaminase; Cas9, CRISPR-associated protein 9; CRISPR, clustered regularly interspaced short palindromic repeats;
D, day; GalNAc, N-acetylgalactosamine; gRNA, guide RNA; LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; LLoQ, lower limit of quantification; LNP, lipid nanoparticle; NHP, non-human
primate, LNPs licensed from Genevant Sciences Corporation.
Single dose of EDIT-401
94%
91%
94%
Pre-dose
24h48h
D8
D15D22D29D43D57D71D85D99
D113D127D141D155D169D183
-100
-90
-80
-70
-60
-50
-40
-30
-20
-10
0
10
20
30
40
Time post dose
LDL-C
(% change from baseline)
Vehicle
(n=4)
1.5 mg/kg
(n=4)
2.0 mg/kg
(n=4)
3.0 mg/kg
(n=4)
UNDER EMBARGO UNTIL MAY 14, 2026
EDIT-401enables increase in LDLR protein levels needed to achieve
≥90% LDL-C reduction in NHPs
A >6-fold mean increase in
LDLR protein in liver resulted in
≥90% LDL-C reduction in NHPs
Approximately 10%–40%
functional editing can lead to the
LDLR protein increase resulting
in ≥90% LDL-C reduction in
NHPs
LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; NHP, non-human primate, LNPs licensed from Genevant Sciences Corporation.
LDL-C vs LDLR protein
051015202530
-100
-80
-60
-40
-20
0
LDLR Protein
(
Fold-change vs. Vehicle in liver homogenate)
LDL-C
(% change from baseline)
R
2
= 0.8926
90%
UNDER EMBARGO UNTIL MAY 14, 2026
Biodistribution
UNDER EMBARGO UNTIL MAY 14, 2026
Highest delivery of EDIT-401 observed in liver as compared to
non-target tissues (assessed by editing levels)
14
Non-target tissue editing
• Low editing detected in adrenal
gland, spleen and ovary of NHP
• No significant editing observed
in any other of 31 total
extrahepatic tissues tested (data
from major organs shown)
Graph show % indelsin LDLR 3’UTR across liver and all non-target tissues.
Representative data shown with one of the EDIT-401 gRNAsby targeted
amplicon sequencing.
D, day; gRNA, guide RNA; LDLR, low-density lipoprotein receptor; NHP, non-human primate, LNPs licensed from Genevant Sciences Corporation.
Single dose of EDIT-401 at 1.5 mg/kg, D29
L
iver
A
drenal g
l
an
d
S
pleen
K
i
d
ney
H
eart
L
ung
s
P
ancrea
s
T
estis
O
vary
0%
5%
10%
15%
20%
25%
% Indels
Vehicle
1.5 mg/kg
UNDER EMBARGO UNTIL MAY 14, 2026
EDIT-401 demonstrates high delivery inhepatocytes and undetectable cargo
in oocytes at therapeutically relevant dose of 1.5 mg/kg
15
Cas mRNA Detected by
In-situ Hybridization (ISH)
Liver (20x)
Ovary (30x)
Consistent results observed with1.5 mg/kg dose and at 3 mg/kg of EDIT-401. Cas9 mRNA detected by in-situ hybridization. Cas9, CRISPR-associated protein 9; IHC, immunohistochemistry; ISH, in-situ hybridization;
LDLR, low-density lipoprotein receptor, LNPs licensed from Genevant Sciences Corporation.
Cas9 mRNA Nuclei Cas9 Protein Nuclei
Positivity restricted to Theca cells
oocyte
Day 29 IHC
Liver (20x)
LDLR Protein Nuclei
oocyte
24hr ISH
24hr IHC
UNDER EMBARGO UNTIL MAY 14, 2026
Safety and tolerability
UNDER EMBARGO UNTIL MAY 14, 2026
No notable treatment-relatedliver enzyme elevations or liver
histopathology findings at therapeutically relevant dose of 1.5 mg/kg
17
EDIT-401 safety
observations at
therapeutically relevant
dose of 1.5 mg/kg:
• Well-tolerated with no
adverse clinical
observations
• Transient ALT
elevations
observed(similar to
vehiclecontrol) with
resolutionin ~1 week
• No liver histopathology
findings
ALT, alanine aminotransferase; AST, aspartate aminotransferase; D, day; NHP, non-human primate, LNPs licensed from Genevant Sciences Corporation.
Data presented from 3 NHP studies
Shaded area represent normal rangeobservedin NHPs
Vehicle dosed with saline following same pre-treatment regimenas EDIT-401
Pre-dosePre-dose
24h48h
D8
D15D22D29
0
100
200
300
400
500
600
Group Mean ALT
Units/L
Vehicle (n=9)
1.5 mg/kg (n=14)
Pre-dosePre-dose
24h48h
D8
D15D22D29
0.0
0.2
0.4
0.6
0.8
1.0
Group Mean Bilirubin
Units/L
Vehicle (n=9)
1.5 mg/kg (n=14)
UNDER EMBARGO UNTIL MAY 14, 2026
Histopathology shows no changes in EDIT-401 treated NHP livers
compared to vehicle on D29
Histopathologic examination was conducted by a board-certified veterinary pathologist or a pathologist with experience and training in toxicologic pathology. No abnormal findings reported in the liver sections
examined from the study in all the animals dosed at 1.5 mg/kg. D, day; H&E, hematoxylin and eosin; IHC, immunohistochemistry; LDLR, low-density lipoprotein receptor; NHP, non-human primate, LNPs
licensed from Genevant Sciences Corporation.
18
Vehicle
1.5 mg/kg EDIT
-401
H&E - Morphology
LDLR IHC
40X
EDIT-401 data at therapeutically
relevant dose of 1.5 mg/kg:
• No evidence of steatosis or
fatty liver was observed, even
in areas of high LDLR IHC
positivity
• Compare to reference image
(below)
Qu P et al. Cell Metabolism, 2023; 35, 742-757.e10
UNDER EMBARGO UNTIL MAY 14, 2026
Conclusions
• EDIT-401 combines Editas'drug development expertiseand Genevant’s LNP to deliver a
differentiated therapeutic strategy of functionalLDLR upregulation
• A single dose of EDIT-401 achieved ≥90% mean LDL-C reduction with ≥6-fold mean
increase in LDLR protein in the NHP liver, requiring only a moderate level of functional
editing of LDLR alleles
• EDIT-401 showed durability of LDL-C reduction across a range of doses through Day 183
• EDIT-401 demonstrated a promising preclinical safety profile in NHPs that was well
tolerated at therapeutically relevant dose.
• Biodistribution data shows highest delivery in hepatocytes with undetectable cargo signal
in oocytes at therapeutically relevant dose
• Encouraging preclinical data supports advancing EDIT-401 towards a first-in-human
clinical trial
CRISPR, clustered regularly interspaced short palindromic repeats; LDLR, low-density lipoprotein receptor; Ldlr, murine low-density lipoprotein receptor; LDL-C, low-density lipoprotein cholesterol; LNP, lipid nanoparticle;
NHP, non-human primate.
19
UNDER EMBARGO UNTIL MAY 14, 2026
Presented preclinical
proof-of-concept data
from NHP and mouse
models
Presentedin vitro
preclinical data
First-in-human
study initiated
20252026
Next Steps & Timing
Submit IND/CTA
by mid-2026
Multi-national
Phase I/II
clinical trial prep
CTA, Clinical Trial Application; IND, Investigational New Drug Application; NHP, non-human primate.
20
UNDER EMBARGO UNTIL MAY 14, 2026
Acknowledgments
Many thanks to my coauthors:
• Judith Newmark
• Parth Amin
• Meetu Seth
• Hank Lin
• Morgan Thompson
• Eugenio Marco
• James Bochicchio
• Salu Rizal
• Wei Zhen
• Paul Wrighton
• Jenny Xie
• Vikram Soman
• Ameya Apte
• Ruhong Dong
• Jared Saffie
• Nassim Ajami
• Linda Burkly
We would like to thank our past colleagues at Editas Medicine. We also thank ourGenevantSciences Corporation collaborators for licensure of
LNPs.Editorial assistance was provided by Porterhouse Medical US and funded by Editas Medicine, Inc. according to Good Publication Practice
(GPP) guidelines.